arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Nautilus Biotechnology, Inc.

NAUT

$2.13 ▼ -0.18 (-7.58%) at close

7 Visible periods

16 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Nautilus Biotechnology, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $268.9M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC —

FCF / Share $-0.41 ↗

Trailing P/E —

Price / Book 1.7x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Nov 5, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-59.00M

↑ +16.6% —

FCF / Share Free cash flow per share

$-0.41

↑ +15.7% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
EPS Growth YoY (%)	16.1% Good ↑ Good Improving Year-over-year change in earnings per share Optimal: > 10%	-9.8% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-10.9% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	23.3% Good Good Year-over-year change in earnings per share Optimal: > 10%	-11.1% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	16.6% Good ↑ Good Improving Year-over-year change in net income	-11.2% Weak ↑ Weak Improving Year-over-year change in net income	-9.9% Weak ↑ Weak Improving Year-over-year change in net income	-15.1% Weak Weak Year-over-year change in net income	-222.1% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	15.7% Good ↑ Good Improving Year-over-year change in free cash flow	-12.7% Weak ↓ Weak Declining Year-over-year change in free cash flow	-12.2% Weak ↓ Weak Declining Year-over-year change in free cash flow	21.4% Good Good Year-over-year change in free cash flow	4.2% Caution Caution Year-over-year change in free cash flow	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
FCF / Net Income (x)	0.88x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.85x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.83x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.83x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.96x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Common Equity (%) (%)	-37.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-351%)	-33.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-326%)	-24.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-260%)	-18.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-223%)	-13.8% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-192%)	52.6% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+250%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Net Debt (USD)	$-12.39M	$-27.65M	$-19.40M	$-114.52M	$-185.62M	$-36.61M	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Basic EPS, GAAP (USD)	$-0.47	$-0.56	$-0.51	$-0.46	$-0.60	$-0.54	—
Free Cash Flow per Share (USD)	$-0.41	$-0.49	$-0.43	$-0.39	$-0.49	$-0.51	—
Book Value per Share (USD)	$1.24	$1.66	$2.12	$2.52	$2.92	$-0.90	—
Tangible Book Value per Share (USD)	$1.24	$1.66	$2.12	$2.52	$2.92	$-0.90	—
Basic Weighted Avg Shares (shares)	126.26M	125.43M	124.92M	124.59M	84.46M	29.09M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$98.01M	$125.19M	$167.72M	$180.42M	$343.41M	$74.64M	—
Total Equity (USD)	$156.97M	$208.73M	$265.35M	$314.92M	$363.58M	$-29.72M	$-14.51M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Depreciation Expense (USD)	$1.70M	$2.00M	$1.85M	$1.22M	$1.02M	$710.00K	—
Net Income, GAAP (USD)	$-59.00M	$-70.78M	$-63.67M	$-57.92M	$-50.31M	$-15.62M	—
Operating Cash Flow (USD)	$-50.70M	$-59.15M	$-51.71M	$-45.81M	$-39.24M	$-14.00M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 7 years · 28 quarters

Nautilus Biotechnology, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare NAUT with peers